Revive Therapeutics (RVVTF) Moves a Step Closer to FDA Verdict
| What Do We Have in April’s Bag of Tricks? 1. Revive Therapeutics (RVVTF) Moves a Step Closer to FDA Verdict 2. Report on Citius Pharma (CTXR): North Shore Research Issues a $10 Price Target, a Potential Gain of 566%. 3. Adding Fintech, Lion Group Holdings (LGHL) $1.27 to Watch List. 4. Smart For Life (SMFL) to Present at The Noble Capital Markets Eighteenth Annual Investor Conference. 5. Adding Smart for Life (SMFL) $0.85 to the Watch List. 6. Report on Mitesco (MITI): Zacks Issues $0.53 Price Target, a 165% Potential Gain. 7. Disclaimer. ______________________________________________________________ 1. Revive Therapeutics (RVVTF) Moves a Step Closer to FDA Verdict. Two Binary Events Directly Ahead. As in Months Away, not Years. Share Price up 76% During April.. As we stated earlier, Revive Therapeutics (RVVTF) is our favorite risk-reward adjusted idea for the year. The clock is ticking..and did we mention this is both our favorite idea and client? FDA Phase III news is due before the end of summer…as in this summer, as in a few months! So don’t tell us the current market is boring. We can’t assure profits, but a position in Revive is going to be anything but boring this summer. Mark our words on that. READ MORE ______________________________________________________________ Report on Citius Pharma (CTXR): North Shore Research Issues a $10 Price Target, a Potential Gain of 566%. We’re Up 181% on Citius Pharma (CTXR), Despite its Being Well Below it’s Recent High of $4.30. We Now Have Two $10 Price Targets. While we don’t issue price targets, we have no disagreement with either their projections or reasoning. At $10, we would be up 1,718% and that ain’t bad! At $5.50, we will have our 14th, 10-bagger client. READ MORE ______________________________________________________________ 3. Adding Fintech, Lion Group Holdings (LGHL) $1.27 to Watch List. Founded in 2015, NASDAQ listed Lion Group (LGHL), offers a sophisticated all-in-one trading platform, permitting investors to participate in nearly all the alternative (and derivative) counter-trend investment ideas above, in addition to traditional equity markets. Lion additionally has interests in SPAC sponsorship (formation). Lion also has fleet of 5,000 Bitmain’s S9 Hydro Antminers capable of generating 0.5 Bitcoins every month. Widely seen as the most powerful bitcoin miner available on the market. What’s not to like? READ MORE ______________________________________________________________ 4. Smart For Life (SMFL) to Present at The Noble Capital Markets Eighteenth Annual Investor Conference. A.J. Cervantes, Jr., Smart for Life’s Executive Chairman will present at the Noble Capital Markets Eighteenth Annual Investor Conference being held on April 20-21, 2022 at the Hard Rock Hotel & Casino in Hollywood, Florida. READ MORE ______________________________________________________________ 5. Adding Smart for Life (SMFL) $0.85 to the Watch List. We’re up 17% from our bottom fishing effort a couple of weeks ago. We think this well-managed “growth by acquisition” play in the $104 billion nutraceutical market which is comprised of 1,000’s of profitable mom-n-pop shops, is destined to provide years of entertaining financial news (acquisitions). A sloppy IPO is giving new investors an unprecedented “buy it early’ opportunity rarely seen. For new to the situation speculative investors, looking for an entry point, it’s better to see Smart for Life drop from its IPO at $10.00 (including warrants) to $0.83 over a period of 30 days – than over a period of one year. Not many people are aware Facebook (FB) dropped from $38 to $18 down 52% after its IPO. The company, in hindsight, wasn’t broken by any means. But the price broke. But most investors were deer in the headlights when it hit $18. Don’t be a deer on this one. The short story on Smart for Life (SMFL) is that it’s a health and wellness consumer products company (vitamins and supplements). They have a game-plan to acquire and roll up in what they call their “Build and Buy” strategy. They have an aggressive objective to build and buy their way to $300 million in revenues, looking out three years. Boo-Ya and go, team. READ MORE ______________________________________________________________ 6. Report on Mitesco (MITI): Zacks Issues $0.53 Price Target, a 165% Potential Gain. Despite a major retreat in share price, we are still up 950% from where we added it to the Watch List in November of 2019. If Chicago-based Zacks (our hometown) is right on their call (we haven’t sold, we’ll be up 2.550% and that ain’t bad. See what Zacks has to say about this growing chain of medical clinics. READ MORE ______________________________________________________________ |
| Copyright © 2022 Internet Stock Review, All rights reserved. Share freely. You are receiving this email because you signed up at our website which has been around since 1998. |
